JPWO2021049606A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021049606A5
JPWO2021049606A5 JP2021545613A JP2021545613A JPWO2021049606A5 JP WO2021049606 A5 JPWO2021049606 A5 JP WO2021049606A5 JP 2021545613 A JP2021545613 A JP 2021545613A JP 2021545613 A JP2021545613 A JP 2021545613A JP WO2021049606 A5 JPWO2021049606 A5 JP WO2021049606A5
Authority
JP
Japan
Prior art keywords
acid sequence
amino acid
dcr3
substitution
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545613A
Other languages
English (en)
Japanese (ja)
Other versions
JP7679300B2 (ja
JPWO2021049606A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/034444 external-priority patent/WO2021049606A1/ja
Publication of JPWO2021049606A1 publication Critical patent/JPWO2021049606A1/ja
Publication of JPWO2021049606A5 publication Critical patent/JPWO2021049606A5/ja
Priority to JP2025077324A priority Critical patent/JP2025121978A/ja
Application granted granted Critical
Publication of JP7679300B2 publication Critical patent/JP7679300B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545613A 2019-09-13 2020-09-11 DcR3改変体 Active JP7679300B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077324A JP2025121978A (ja) 2019-09-13 2025-05-07 DcR3改変体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019167728 2019-09-13
JP2019167728 2019-09-13
PCT/JP2020/034444 WO2021049606A1 (ja) 2019-09-13 2020-09-11 DcR3改変体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077324A Division JP2025121978A (ja) 2019-09-13 2025-05-07 DcR3改変体

Publications (3)

Publication Number Publication Date
JPWO2021049606A1 JPWO2021049606A1 (https=) 2021-03-18
JPWO2021049606A5 true JPWO2021049606A5 (https=) 2023-09-19
JP7679300B2 JP7679300B2 (ja) 2025-05-19

Family

ID=74865719

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545613A Active JP7679300B2 (ja) 2019-09-13 2020-09-11 DcR3改変体
JP2025077324A Pending JP2025121978A (ja) 2019-09-13 2025-05-07 DcR3改変体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077324A Pending JP2025121978A (ja) 2019-09-13 2025-05-07 DcR3改変体

Country Status (10)

Country Link
US (1) US20220340642A1 (https=)
EP (1) EP4056232B1 (https=)
JP (2) JP7679300B2 (https=)
KR (1) KR20220061967A (https=)
CN (3) CN121930331A (https=)
AU (1) AU2020346580A1 (https=)
BR (1) BR112022004590A2 (https=)
CA (1) CA3154191A1 (https=)
TW (1) TW202124425A (https=)
WO (1) WO2021049606A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ctla-4変異型免疫調節タンパク質およびそれらの使用
US20230159649A1 (en) * 2020-04-02 2023-05-25 La Jolla Institute For Immunology Methods and combinations for dual targeting of tnf family members
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
EP4370545A1 (en) * 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
TW202545974A (zh) * 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任(Vii)公司 免疫受體抑制蛋白及相關方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT311902B (de) 1970-04-29 1973-10-15 Herrmann W Ionenaustauschfilter,insbesondere kleinfilter
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
JP4303883B2 (ja) * 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド DcR3ポリペプチドというTNFR相同体
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
US6965012B1 (en) 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
US6835814B1 (en) 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
BRPI0519008A2 (pt) * 2004-12-13 2008-12-23 Evogenix Ltd proteÍnas variantes de osteoprotegerina
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
EP2653540B9 (en) 2010-12-15 2018-05-16 Inter-University Research Institute Corporation Research Organization of Information and Systems Protein production method
US20140193410A1 (en) * 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
ES2894963T3 (es) * 2013-05-17 2022-02-16 Cedars Sinai Medical Center Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
EP3730188B1 (en) * 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases

Similar Documents

Publication Publication Date Title
JPWO2021049606A5 (https=)
ES2327409T3 (es) Proteinas de fusion fc mejoradas.
ES2298785T3 (es) Proteinas de fusion.
ES2239242T3 (es) Inmunoadhesion concatemerica.
US8193316B2 (en) TACI-Fc fusion proteins, methods of making and uses thereof
KR101474817B1 (ko) 개선된 sgp130Fc 이량체
US7576190B2 (en) FGF-21 fusion proteins
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
KR20140069249A (ko) 대사 장애를 치료하기 위한 이중 기능 단백질
JP2023518443A5 (https=)
CA2428242A1 (en) Human tumor necrosis factor receptor
CN102770458A (zh) 用于增加Fc融合蛋白的血清半寿期的组合物和方法
JPH08507201A (ja) リンホトキシン‐β、リンホトキシン‐β複合体、それらの薬学的な調製物および治療への使用
JP2008515970A (ja) キメラタンパク質
WO2018166468A1 (zh) IgG样长效免疫融合蛋白及其应用
CN108948207A (zh) 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
US7700318B2 (en) Chimeric polypeptide and use thereof
CN116113428A (zh) 白细胞介素-2突变蛋白及其用途
WO2023125881A1 (zh) Glp-1和gdf15的融合蛋白及其用途
JP2013253079A (ja) 生物学的に活性なヒト尿中トリプシンインヒビターのFc融合タンパク質並びにその調製および使用
WO2022188883A1 (zh) Tnfr2与april/baff受体的融合蛋白
EP2586793A1 (en) Chimeric molecule involving oligomerized FasL extracellular domain
RU2815388C2 (ru) Многофункциональные слитые белки и их применения
CN101166757A (zh) 新的嵌合多肽及其应用
WO2023025123A1 (zh) Gdf15融合蛋白及其用途